BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 24343625)

  • 1. Diagnosis and treatment of Paget's disease of bone: a mini-review.
    Ferraz-de-Souza B; Correa PH
    Arq Bras Endocrinol Metabol; 2013 Nov; 57(8):577-82. PubMed ID: 24343625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Zoledronic acid for treatment of Paget's disease of bone.
    Devogelaer JP; Manicourt DH
    Expert Opin Pharmacother; 2007 Nov; 8(16):2863-9. PubMed ID: 17956205
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Persistent effect of zoledronic acid in Paget's disease.
    Tziomalos K; Florentin M; Krikis N; Perifanis V; Karagiannis A; Harsoulis F
    Clin Exp Rheumatol; 2007; 25(3):464-6. PubMed ID: 17631747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Normal bone turnover markers in a patient with active Paget's disease of bone: response to treatment with zoledronic acid.
    Polyzos SA; Anastasilakis AD; Anagnostis P; Kita M; Arsos G; Moralidis E; Papatheodorou A; Terpos E
    Endokrynol Pol; 2012; 63(4):312-5. PubMed ID: 22933168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paget's disease of bone: A clinical update.
    Cook SJ; Wall C
    Aust J Gen Pract; 2021; 50(1-2):23-29. PubMed ID: 33543158
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of patients with Paget's disease: a consensus document of the Belgian Bone Club.
    Devogelaer JP; Bergmann P; Body JJ; Boutsen Y; Goemaere S; Kaufman JM; Reginster JY; Rozenberg S; Boonen S;
    Osteoporos Int; 2008 Aug; 19(8):1109-17. PubMed ID: 18504638
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of zoledronic acid for Paget's disease of bone.
    Maricic M
    Curr Osteoporos Rep; 2006 Mar; 4(1):40-4. PubMed ID: 16527007
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of intravenous aminobisphosphonates for the treatment of Paget's disease of bone.
    Gennari L; Merlotti D; Mossetti G; Rendina D; De Paola V; Martini G; Nuti R
    Mini Rev Med Chem; 2009 Aug; 9(9):1052-63. PubMed ID: 19689402
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Symptomatic intracranial hypertension and prolonged hypocalcemia following treatment of Paget's disease of the skull with zoledronic acid.
    Ferraz-de-Souza B; Martin RM; Correa PH
    J Bone Miner Metab; 2013 May; 31(3):360-5. PubMed ID: 23076294
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paget's disease of bone and calcium homeostasis: focus on bisphosphonate treatment.
    Polyzos SA; Anastasilakis AD; Makras P; Terpos E
    Exp Clin Endocrinol Diabetes; 2011 Oct; 119(9):519-24. PubMed ID: 21811962
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A review of Paget's disease of bone with a focus on the efficacy and safety of zoledronic acid 5 mg.
    Abelson A
    Curr Med Res Opin; 2008 Mar; 24(3):695-705. PubMed ID: 18226324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bisphosphonates for Paget's disease of bone in adults.
    Corral-Gudino L; Tan AJ; Del Pino-Montes J; Ralston SH
    Cochrane Database Syst Rev; 2017 Dec; 12(12):CD004956. PubMed ID: 29192423
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Treatment of Paget's disease of bone with zoledronic acid].
    Body JJ; Sternon J
    Rev Med Brux; 2005; 26(6):513-7. PubMed ID: 16454155
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Zoledronic acid: a review of its use in the treatment of Paget's disease of bone.
    Keating GM; Scott LJ
    Drugs; 2007; 67(5):793-804. PubMed ID: 17385948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Profound hypocalcemia following effective response to zoledronic acid treatment in a patient with juvenile Paget's disease.
    Polyzos SA; Anastasilakis AD; Litsas I; Efstathiadou Z; Kita M; Arsos G; Moralidis E; Papatheodorou A; Terpos E
    J Bone Miner Metab; 2010 Nov; 28(6):706-12. PubMed ID: 20533067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Scintigraphic, biochemical, and clinical response to zoledronic acid treatment in patients with Paget's disease of bone.
    Avramidis A; Polyzos SA; Moralidis E; Arsos G; Efstathiadou Z; Karakatsanis K; Grollios G; Kita M
    J Bone Miner Metab; 2008; 26(6):635-41. PubMed ID: 18979164
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Paget's disease: case report].
    Wegierska M; Ignaczak P; Zalewska J; Jeka S
    Ann Acad Med Stetin; 2011; 57(3):64-9; discussion 69. PubMed ID: 23383549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Zoledronic acid for Paget's disease of bone.
    Maricic M
    Drugs Today (Barc); 2007 Dec; 43(12):879-85. PubMed ID: 18174973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug treatment strategies for paget's disease: relieving pain and preventing progression.
    Merlotti D; Rendina D; Cavati G; Abate V; Falchetti A; Mingiano C; Nuti R; Gennari L
    Expert Opin Pharmacother; 2023 Apr; 24(6):715-727. PubMed ID: 36961938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paget's disease of bone: analysis of 134 cases from an island in Southern Brazil: another cluster of Paget's disease of bone in South America.
    Werner de Castro GR; Heiden GI; Zimmermann AF; Morato EF; Neves FS; Toscano MA; de Magalhães Souza Fialho SC; Pereira IA
    Rheumatol Int; 2012 Mar; 32(3):627-31. PubMed ID: 21127877
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.